Day: April 3, 2020

Westport, CT, April 03, 2020 (GLOBE NEWSWIRE) —Introduction to ViralClear management and scientific teamStrategy for rapid FDA advancement of Vicromax(tm)Update on BioSig core business developments and commercialization plansBioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that it intends to provide a public business update via teleconference regarding its recently acquired anti-viral pharmaceutical candidate, Vicromax(tm). The briefing is being held on Tuesday, April 7, 2020 at 11am ET.ViralClear Pharmaceuticals, Inc. will be represented by Nick Spring, CEO, Steven King, COO and Jerome Zeldis, M.D., Ph.D, Executive Chair. BioSig will be represented by Kenneth L. Londoner, MBA, Chairman and CEO of...

MONTHLY DECLARATION OF THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES(ARTICLE L233-8II THE COMMERCIAL CODE and 223-16 OF THE GENERAL REGULATIONS OF THE FINANCIAL MARKETS AUTHORITY (AMF))Paris, 3rd  April, 2020MARIE BRIZARD WINE & SPIRITSISIN Code: 0000060873Do the Marie Brizard Wine & Spirits SA by-laws contain a clause requiring disclosure of the crossing of any statutory thresholds in addition to that relating to legal thresholds: yes.Including treasury sharesAfter deduction of treasury shares AttachmentMBWS_MONTHLY DECLARATION OF THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES_March 2020

VANCOUVER, British Columbia, April 03, 2020 (GLOBE NEWSWIRE) — Pepcap Resources, Inc. (TSXV-WAV.H) (“Pepcap” or the “Company”) announces that Gek Suan Margaret Wee has resigned as a member of the board of directors of the Company (the “Board”). The Board has accepted the resignation of Ms. Wee and wishes to thank her for her contributions to the Company.On behalf of the Board of Directors:PEPCAP RESOURCES, INC.Tek Sian (Alan) KwanPresident, Chief Executive Officer and DirectorFor further information, please contact: Tek Sian (Alan) KwanPhone: +1-61-40-301-8601Email: alan@onetechplatform.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Ageas has today released a set of 2019 reports consisting of two separate publications:the Annual Report 2019 including the Report of the Board of Directors, the Ageas Consolidated Financial Statements, and the 2019 Statutory Accounts of ageas SA/NV;the Business Report 2019 providing an overview of Ageas’s businesses around the world, a snapshot of its accomplishments in 2019, alongside its future ambitions.These publications are accessible through the Investors pages on the Ageas website and on a specific website dedicated to the 2019 performance: reporting2019.ageas.com.The 2019 annual results were published on 19 February 2020.Ageas is a listed international insurance Group with a heritage spanning almost 200 years. It offers Retail and Business customers Life and Non-Life insurance products designed to suit their specific needs,...

Ageas a publié aujourd’hui le recueil ‘Reporting 2019’, qui se compose de deux publications distinctes:le Rapport annuel 2019, composé du Rapport du Conseil d’Administration d’Ageas, des États financiers consolidés d’Ageas et des Comptes Statutaires d’ageas SA/NV pour l’année 2019 ;le Rapport d’Activité 2019, qui donne un aperçu des réalisations d’Ageas en 2019, de ses diverses activités dans le monde, ainsi que de ses ambitions pour l’avenir.Ces publications sont accessibles via les pages Investisseurs du site Internet d’Ageas et via le site Internet dédié à la performance d’Ageas en 2019 : reporting2019.ageas.com.Les résultats annuels 2019 ont été publiés le 19 février 2020.Ageas est un groupe d’assurance international coté en bourse, riche de quelques 190 années d’expérience...

Ageas publiceert vandaag zijn verslaggeving over 2019 bestaande uit twee aparte publicaties:het Jaarverslag 2019, bestaande uit het Verslag van de Raad van Bestuur van Ageas, de Geconsolideerde Jaarrekening van Ageas en de Statutaire Jaarrekening van ageas SA/NV voor 2019; het Activiteitenverslag 2019 dat een overzicht geeft van alle verwezenlijkingen van Ageas in 2019, zijn activiteiten wereldwijd en de toekomstige ambities.Deze publicaties zijn beschikbaar op de Investeerders pagina’s van de Ageas website en op de specifieke website voor de resultaten van 2019: reporting2019.ageas.com.De jaarresultaten van Ageas voor 2019 werden via het persbericht van 19 februari 2020 bekendgemaakt.Ageas is een beursgenoteerde internationale verzekeringsgroep met 190 jaar vakkennis en ervaring. Het biedt zowel particulieren als bedrijven Levens- en...

Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de Commerce et l’article 223-16 du règlement général de l’Autorité des marchés financiers (AMF)Situation au 31 mars 2020Ce document est accessible en PDF sur le site de la Société,dans la rubrique Information réglementée www.iliad.fr   Pièce jointedeclaration_drts_votes_310320

EURONEXT ANNOUNCES VOLUMES FOR MARCH 2020Amsterdam, Brussels, Dublin, Lisbon, London, Oslo and Paris –  3 April 2020 – Euronext, the leading pan-European exchange in the Eurozone, today announced trading volumes for March 2020.Monthly and historical volumes table are available at this address:https://www.euronext.com/en/investor-relations#monthly-volumesCONTACTS –MediaPauline Bucaille                                     +33 1 70 48 24 41; pbucaille@euronext.com Analysts & investorsAurélie Cohen/ Clément Kubiak            +33 1 70 48 24 27; ir@euronext.comAbout EuronextEuronext is the leading pan-European exchange, covering Belgium, France, Ireland, The Netherlands, Norway, Portugal and the UK. With close to 1,500 listed issuers worth €3.3 trillion in market capitalisation as of end March 2020, Euronext has an unmatched blue...

STOCKHOLM, SWEDEN – April 3, 2020. Karolinska Development (Nasdaq Stockholm: KDEV) announces that its portfolio company Umecrine Cognition has reported top-line data from a clinical phase 2a study of the drug candidate golexanolone in patients at risk of developing hepatic encephalopathy. Results demonstrate a positive safety and tolerability profile; however, no indications of clinical effects could be observed. The results will be further analyzed in order to evaluate if continued clinical development of golexanolone is merited. Such a decision is planned within the second quarter of 2020, at which point Karolinska Development will disclose the impact on the book value of its holding in Umecrine Cognition.The intended use of golexanolone (GR3027) is to reduce cognitive impairment and other severe CNS symptoms, and the risk of hepatic...